| Announcement | Date |
|---|---|
Exact Sciences and Pfizer Enter into a U.S. Agreement for Cologuard®On August 22, 2018, Exact Sciences Corp. and Pfizer Inc. announced an agreement to co-promote Cologuard, the FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer joins Exact Sciences' colleagues in reaching both physicians and health systems and also actively participates in extending and deepening the Cologuard development. For further medical information, please call Exact Sciences Provider Support Line 1-844-870-8870 |
October 8, 2018 |
U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic NSCLCOn September 27, 2018, the U.S. FDA approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. The safety and efficacy of VIZIMPRO was demonstrated in the randomized, open-label, phase 3 study, ARCHER 1050 (NCT01774721). Please see the full press release via the link below for further details. |
September 28, 2018 |
Nivestym FDA ApprovalU.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi) |
July 24, 2018 |
Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, due to Infusion Reactions |
June 29, 2018 |
FDA approves Xeljanz for moderately to severely active ulcerative colitis |
May 30, 2018 |
Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ |
May 24, 2018 |
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDAOn 5/15/2018, Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa), for all indications of the reference product. Please see the full press release via the link below for further details. |
May 15, 2018 |
Overview of Quillivant XR (video presentation) |
February 22, 2017 |